<DOC>
	<DOCNO>NCT01510847</DOCNO>
	<brief_summary>The study hypothesis treatment oral Testosterone accord study regimen improve glycemic control T2DM Chinese male Singapore indicate reduction HbA1c level study day 90 .</brief_summary>
	<brief_title>The Effect 90-day Oral Testosterone Therapy Chinese Males With Type 2 Diabetes ( T2DM )</brief_title>
	<detailed_description>This single arm open label clinical study Chinese men 45 75 year age Type 2 Diabetes . Subjects recruit participate family medicine clinic FMRN follow 90-days . All subject continue pre-study treatment regimen medication clinically indicate throughout 90-day study period . Missed dos study drug make within day . With exception study drug diabetic medication , change medication permit . The primary aim ass effect oral Testosterone change HbA1c level Chinese male diagnosis T2DM 90-day study period . Subjects enrol study take two 40mg capsule oral testosterone morning two 40mg capsule even meal occasion day . This daily dosage consistent recommend dosage subject treat hypogonadism . Primary objective : - The primary aim ass effect oral Testosterone percent change HbA1c T2DM Chinese male Singapore 90-day study period . Secondary objective : - The secondary aim ass effect site , eugonadism hypogonadism , prognostic relevance baseline level HbA1c , total testosterone , PSA , IPSS , haemoglobin haematocrit 90-day change percent change baseline HbA1c study Testosterone regimen . All subject must satisfy ALL follow criterion study entry : - Subject Chinese male - Subject 45 75 year old - Subject T2DM change type/dose diabetic medication last 3 month - Subject 's Haemoglobin level 13.5 - 18g/dl - Subject 's Haematocrit level 40 - 54 % - Subject 's Albumin level 3.5 - 5.0 g/dL - Subject 's Alanine transaminase ( ALT ) level 36 U/L - Subject 's Aspartate transaminase ( AST ) level &lt; 41 U/L - Subject 's Alkaline phosphatase ( ALP ) level &lt; 130 U/L - Subject 's Creatinine ( 60 year ) level 0.57 - 1.36 mg/dL - Subject 's Creatinine ( &gt; 60 year ) level 0.68 - 1.48 mg/dL - Subject 's Sodium ( 13 65 year ) level 136 - 145 mmol/L - Subject 's Sodium ( &gt; 65 year ) level 132 - 146 mmol/L - Subject 's Potassium ( 59 year ) level 3.3 - 5.1 mmol/L - Subject 's Potassium ( &gt; 59 year ) level 3.7 - 5.4 mmol/L - Subject 's PSA ( Prostate Specific Antigen ) level ≤ 4ug/L - Subject 's Total Testosterone level 8.4 - 28.7 nmol/L - Satisfactory haematological biochemical function test - test carry screening period prior enrolment . Patient mild laboratory abnormality include discretion site/co-investigator , approval Co-ordinating Principal Investigator - Written Informed Consent obtain - Subject willing comply study procedure able return clinic schedule visit All subject must NOT follow criterion study entry : - Subject 's HbA1C level &gt; 9 % . - Subject insulin therapy - Subject history recurrent hypoglycaemia - Subject history malignancy ( except skin cancer ) last 5 year - Subject receive treatment endocrinopathy within last 3 month ( except diabetes ) - Subject history adverse drug reaction testosterone - Subject receive testosterone replacement within last 3 month - Subject currently receive warfarin , steroid , cyclosporine thyroxine - Subject history Myocardial Infarction - Subject history Angina - Subject heart failure cause least slight limitation physical activity . Subject comfortable rest , ordinary physical activity result fatigue , palpitation dyspnea - Subject history Deep Vein Thrombosis Stroke - Subject history prostate cancer - Subject history chronic kidney disease , Stage 3 bad - Subject life expectancy le 1 year - Subject enlarge prostate per digital rectal examination - Subject 's International Prostate Symptom Score ( IPSS ) great 20 Blood sample draw study period : - 16 type blood sample Baseline , Month 1 Month 3 Visits . - HbA1c , Haemoglobin , Haematocrit , Albumin , ALT , AST , ALP , Creatinine , PSA , Total Testosterone , Total Cholesterol , HDL , LDL , Triglycerides , Sodium , Potassium</detailed_description>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Subject Chinese male Subject 45 75 year old Subject T2DM change type/dose diabetic medication last 3 month Subject 's Haemoglobin level 13.5 18g/dl Subject 's Haematocrit level 40 54 % Subject 's Albumin level 3.5 5.0 g/dL Subject 's Alanine transaminase ( ALT ) level 36 U/L Subject 's Aspartate transaminase ( AST ) level &lt; 41 U/L Subject 's Alkaline phosphatase ( ALP ) level &lt; 130 U/L Subject 's Creatinine ( 60 year ) level 0.57 1.36 mg/dL Subject 's Creatinine ( &gt; 60 year ) level 0.68 1.48 mg/dL Subject 's Sodium ( 13 65 year ) level 136 145 mmol/L Subject 's Sodium ( &gt; 65 year ) level 132 146 mmol/L Subject 's Potassium ( 59 year ) level 3.3 5.1 mmol/L Subject 's Potassium ( &gt; 59 year ) level 3.7 5.4 mmol/L Subject 's PSA ( Prostate Specific Antigen ) level ≤ 4ug/L Subject 's Total Testosterone level 8.4 28.7 nmol/L Satisfactory haematological biochemical function test test carry screening period prior enrolment . Patient mild laboratory abnormality include discretion site/coinvestigator , approval Coordinating Principal Investigator Written Informed Consent obtain Subject willing comply study procedure able return clinic schedule visit Subject 's HbA1C level &gt; 9 % . Subject insulin therapy Subject history recurrent hypoglycaemia Subject history malignancy ( except skin cancer ) last 5 year Subject receive treatment endocrinopathy within last 3 month ( except diabetes ) Subject history adverse drug reaction testosterone Subject receive testosterone replacement within last 3 month Subject currently receive warfarin , steroid , cyclosporine thyroxine Subject history Myocardial Infarction Subject history Angina Subject heart failure cause least slight limitation physical activity . Subject comfortable rest , ordinary physical activity result fatigue , palpitation dyspnea Subject history Deep Vein Thrombosis Stroke Subject history prostate cancer Subject history chronic kidney disease , Stage 3 worse Subject life expectancy le 1 year Subject enlarge prostate per digital rectal examination Subject 's International Prostate Symptom Score ( IPSS ) great 20</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>